The Zhitong Finance App learned that amlitelimab (amlitelimab), a next-generation experimental asthma drug developed by SNY.US (SNY.US), failed to significantly reduce the number of episodes of the disease, overshadowed the drug's prospects, making it difficult to bear the burden of making up for the losses caused by the expiration of the patent for Sanofi's major drug dupixent (Dupixent).

The Zhitong Finance App learned that amlitelimab (amlitelimab), a next-generation experimental asthma drug developed by SNY.US (SNY.US), failed to significantly reduce the number of episodes of the disease, overshadowed the drug's prospects, making it difficult to bear the burden of making up for the losses caused by the expiration of the patent for Sanofi's major drug dupixent (Dupixent).